ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Oxfordbiotherapeutics
Oxford Biotherapeutics (OBT) is a clinical‑stage biotechnology company focused on developing innovative antibody‑based cancer therapeutics. The company is advancing its immuno‑oncology pipeline with cutting-edge discovery platforms and a strong collaborative network.
Headquarters
Oxford, England, United Kingdom
Company Size
11-50 employees
Founded
2004
Oxford BioTherapeutics is a biotechnology company focused on developing first‑in‑class oncology therapies. They pioneer targeted approaches including Antibody‑Drug Conjugates (ADCs), immuno‑oncology agents, T‑Cell Engagers (TCEs), and radiopharmaceuticals. The company advances a pipeline driven by translational science and strategic partnerships to accelerate delivery of novel cancer treatments to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Oxfordbiotherapeutics.
7% above the average for this role
Senior Scientist, Antibody Repertoire Sequencing & Discovery
AbbVie
Senior Analyst – Antibody Discovery
Elanco
Senior Scientist - Display Technologies (Antibody Discovery)
Cancer Research UK
Antibody Discovery Scientist
Gilead Sciences
Senior Scientist, Antibody Repertoire Sequencing & Discovery
AbbVie
Senior Scientist, Antibody and Protein Engineering
Regeneron Pharmaceuticals